Google fiercepharma website for below:
“In approving Ojjaara in the first line, the FDA also considered a subgroup analysis of the failed SIMPLIFY-1 trial in patients with anemia.””Now, the FDA appears to think that Ojjaara doesn’t have to beat Jakafi to deserve a first-line nod. Miels said he views this
https://www.fiercepharma.com/pharma/pleasant-surprise-gsk-fda-approves-jak-drug-momelotinib-broader-blood-cancer-use as “a recognition there’s a very elegant mechanism at play.”
Yawn.
Cell Therapy News/Articles, page-17130
-
- There are more pages in this discussion • 772 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |